KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Cash from Investing Activities: 2010-2025

Historic Cash from Investing Activities for Pacira BioSciences (PCRX) over the last 16 years, with Sep 2025 value amounting to $43.6 million.

  • Pacira BioSciences' Cash from Investing Activities rose 183.61% to $43.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.8 million, marking a year-over-year increase of 207.04%. This contributed to the annual value of -$83.3 million for FY2024, which is 207.40% down from last year.
  • According to the latest figures from Q3 2025, Pacira BioSciences' Cash from Investing Activities is $43.6 million, which was down 29.84% from $62.2 million recorded in Q2 2025.
  • Pacira BioSciences' Cash from Investing Activities' 5-year high stood at $66.9 million during Q4 2021, with a 5-year trough of -$208.0 million in Q1 2022.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$368,000 (2024), whereas its average is $6.8 million.
  • In the last 5 years, Pacira BioSciences' Cash from Investing Activities skyrocketed by 531.75% in 2022 and then crashed by 1,101.36% in 2024.
  • Pacira BioSciences' Cash from Investing Activities (Quarterly) stood at $66.9 million in 2021, then tumbled by 83.28% to $11.2 million in 2022, then dropped by 25.16% to $8.4 million in 2023, then plummeted by 104.39% to -$368,000 in 2024, then soared by 183.61% to $43.6 million in 2025.
  • Its Cash from Investing Activities was $43.6 million in Q3 2025, compared to $62.2 million in Q2 2025 and -$25.6 million in Q1 2025.